QUT spinout Microbio has developed a breakthrough pathogen test transforming the detection of sepsis—a silent killer responsible for 11 million deaths annually* worldwide.
Based at TRI, this biotech scale-up is pioneering blood testing with its InfectID products, which rapidly identify bacterial, fungal and viral infections. Every hour of delayed treatment increases sepsis mortality by 7.6%**, and InfectID-BSI detects blood-borne pathogens leading to sepsis and septic shock about 13 hours faster*** than conventional methods. Particularly valuable for developing regions with limited healthcare infrastructure, Microbio’s technology is already commercially available in Europe, the UK and India.
With A$3.5m raised in 2022, the company is conducting clinical trials at BRIJ in pursuit of Australian and US regulatory approval, expanding its manufacturing capacity and exploring applications.
3
markets launched (Europe, UK, India)
13 hours
faster pathogen detection
A$3.5m
raised in 2022
Sources
* WHO Global Report on the Epidemiology and Burden of Sepsis, Sept 2020
** American Journal of Respiratory and Critical Care Medicine, Oct 2017
*** Journal of Microbiological Methods, Aug 2023
